Immunic (NASDAQ:IMUX) Earns “Buy” Rating from D. Boral Capital

Immunic (NASDAQ:IMUX)‘s stock had its “buy” rating reiterated by equities researchers at D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $17.00 target price on the stock.

Other equities research analysts have also issued reports about the company. EF Hutton Acquisition Co. I upgraded Immunic to a “strong-buy” rating in a report on Monday, September 16th. Leerink Partners reissued an “outperform” rating and issued a $5.00 target price on shares of Immunic in a research report on Monday, September 9th. HC Wainwright initiated coverage on shares of Immunic in a report on Monday, November 25th. They set a “buy” rating and a $10.00 price target on the stock. Leerink Partnrs upgraded shares of Immunic to a “strong-buy” rating in a report on Monday, September 9th. Finally, StockNews.com lowered Immunic from a “hold” rating to a “sell” rating in a report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Immunic presently has a consensus rating of “Buy” and a consensus price target of $12.67.

Immunic Trading Down 1.8 %

Shares of NASDAQ:IMUX opened at $1.10 on Tuesday. The firm has a market cap of $99.09 million, a price-to-earnings ratio of -0.89 and a beta of 1.88. Immunic has a 1 year low of $0.97 and a 1 year high of $2.11. The business has a fifty day simple moving average of $1.14 and a 200 day simple moving average of $1.32.

Insider Activity

In related news, Director Richard Alan Rudick purchased 87,300 shares of the firm’s stock in a transaction on Tuesday, November 12th. The shares were bought at an average cost of $1.15 per share, for a total transaction of $100,395.00. Following the transaction, the director now directly owns 87,300 shares of the company’s stock, valued at approximately $100,395. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 3.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Immunic

Several hedge funds have recently made changes to their positions in the stock. Connor Clark & Lunn Investment Management Ltd. increased its stake in Immunic by 70.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after acquiring an additional 42,383 shares during the period. State Street Corp increased its position in shares of Immunic by 7.5% during the third quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after purchasing an additional 11,642 shares during the period. Jane Street Group LLC increased its position in shares of Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after purchasing an additional 38,553 shares during the period. Finally, Virtu Financial LLC acquired a new position in shares of Immunic in the third quarter valued at $50,000. Institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.